Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan

Date

14 Sep 2024

Session

Poster session 10

Topics

Immunotherapy

Tumour Site

Oesophageal Cancer;  Renal Cell Cancer;  Gastric Cancer;  Urothelial Cancer;  Non-Small Cell Lung Cancer;  Head and Neck Cancers

Presenters

Tomoya Ohno

Citation

Annals of Oncology (2024) 35 (suppl_2): S937-S961. 10.1016/annonc/annonc1606

Authors

T. Ohno1, T.J. Flottemesch2, R. Aguiar-Ibanez3, K. Srviastava4, J. Chou5, L. Liu6

Author affiliations

  • 1 Merck Research Laboratories, MSD K.K., 102-8667 - Chiyoda-ku/JP
  • 2 Health Economics And Outcomes Research, Precision Value and Health, 10165 - New York/US
  • 3 Merck Canada, MSD Netherlands, 2031BN - Haarlem/NL
  • 4 Precisionheor, Precision Value and Health, 10165 - New York/US
  • 5 Precisionheor, PRECISIONheor - Precision Medicine Group, LLC, 94612 - Oakland/US
  • 6 Oncology, Weill Cornell Medical College, 10065 - New York/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1555P

Background

Approved for 17 cancers in Japan, use of IO therapy has steadily increased since 2014. For four IO therapies (nivolumab, pembrolizumab, atezolizumab, and durvalumab), we modeled life years saved (LYS), the social value of those LYS, and how that value distributes across manufacturers and society for six, high-burden, advanced/recurrent cancers (non-small cell lung cancer, renal, head and neck squamous cell carcinoma, gastric, urothelial, and endometrial) in Japan.

Methods

A model of IO therapy treatment for six cancers estimated LYS and their monetized value. Per-person survival gains were estimated using digitized overall survival curves relative to a prior treatment standard reported by landmark clinical trials supporting IO therapy approval for each cancer. These per-person gains were scaled to the Japanese population using data from a nationally representative hospital treatment database and monetized to total social value using published estimates of the value of a statistical life year based upon human capital and willingness to pay approaches. Manufacturer and societal shares using time-varying drug and administrative costs were calculated. A 5-year timeframe beginning Jan 1, 2017, comprised our base-case. The impact of analytic timeframe, rates of IO therapy utilization, time on treatment, and treatment efficacy were explored in univariate sensitivity analyses.

Results

The base-case indicated the four IO therapies resulted in 8,851 LYS among patients with the six modeled cancers for a net social value of ¥244B (benefit less treatment costs) of which 86.5% (¥211B) was classified as social surplus (share of value to patients and other parts of society) versus 13.5% (¥33B) to manufacturers (manufacturer share). Estimates were most sensitive to analytic timeframe. Over a 10-year timeframe, an additional 28,715 patients would receive IO therapy for these cancers resulting in 17,863 additional LYS for a ¥509B increase in net social value. While ¥94B additional treatment costs are incurred, the manufacturer share of social value decreased to 4.9%.

Conclusions

In Japan among six high-burden cancers, treatment with four IO therapies has generated substantial social value, and the societal share of that value has increased over time and with increased therapy use.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Merck Sharp & Dohme LLC.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.